Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 4, 2011, Pages 834-843

  Benslimane Ahmim, Z ^a   Heymann, D ^b,c   Dizier, B ^a   Lokajczyk, A ^a,d   Brion, R ^b   Laurendeau, I ^a   Bieche I ^a   Smadja, D M ^a,d,e   Galy Fauroux, I ^a,d   Colliec Jouault, S ^f   Fischer, A M ^a,d,e   Boisson Vidal, C ^a  

^a INSERM   (France)

^b Universite de Nantes   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f IFREMER   (France)

Author keywords

Endothelial colony forming cells; Osteoprotegerin; Receptor activator of nuclear factor B ligand; Vasculogenesis

Indexed keywords

ANGIOPOIETIN RECEPTOR; CD31 ANTIGEN; CD34 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; HEMOGLOBIN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIGEL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL ACTIVITY; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CHEMOTAXIS; COLONY FORMING CELL; CONTROLLED STUDY; CORRELATIONAL STUDY; ENDOTHELIAL COLONY FORMING CELL; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MICROVASCULATURE; MORPHOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVASCULARIZATION; SIGNAL TRANSDUCTION; UMBILICAL CORD; UPREGULATION; VASCULARIZATION;

ANIMALS; BLOOD VESSELS; BLOTTING, WESTERN; CELL PROLIFERATION; CHEMOTAXIS; FIBROBLAST GROWTH FACTOR 2; FLOW CYTOMETRY; HUMANS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOPROTEGERIN; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79953323463     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04207.x     Document Type: Article

References (49)

1. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8: 464-78.
2. Heil M, Eitenmüller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2007; 10: 45-55.
3. McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009; 12: 35-46.
4. Reid PE, Brown NJ, Holen I. Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact. Mol Cancer 2009; 8: 49-59.
5. Cross SS, Yang Z, Brown NJ, Balasubramaniam SP, Avans CA, Woodwards JK. Osteoprotegerin (OPG) - a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 2006; 118: 1901-8.
6. Baud'huin M, Lamoureux F, Duplomb L, Rédini F, Heymann D. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 2007; 64: 2334-50.
7. Ando K, Mori K, Redini F, Heymann D. RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol 2008; 5: 263-8.
8. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-23.
9. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98: 3534-40.
10. Morony S, Capparelli C, Sarosi I. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61: 4432-6.
11. Wittrant Y, Théoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004; 1704: 49-57.
12. Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007; 40: 471-8.
13. Chanda D, Isayeva T, Kumar S, Seigal GP, Szafran AA, Zinn KR. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol Ther 2008; 16: 871-8.
14. Bucay N, Sarosi I, Dunstan CR, Morony S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 2008; 12: 1260-8.
15. Fili S, Karalaki M, Schaller B. Therapeutic implications of osteoprotegerin. Cancer Cell Int 2009; 12: 9-26.
16. Kees M, Wiesbauer F, Gisslinger B, Wagner R, Shehata M, Gisslinger H. Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera. Thromb Haemost 2005; 93: 70-5.
17. Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, Hashimoto H, Ikari Y. Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost 2010; 8: 1170-5.
18. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure. Circulation 2005; 111: 2461-8.
19. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 1046-57.
20. Mizuno A, Amizuka N, Irie K, Murakami A, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247: 610-5.
21. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA. Relation of osteoprotegerin to coronary calcium and aortic plaque. Am J Cardiol 2007; 99: 513-8.
22. Secchiero P, Corallini F, Beltrami AP, Ceconi C, Bonasia V, Di Chiara A, Ferrari R, Zauli G. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010; 210: 274-7.
23. Chikatsu N, Takeuchi Y, Fukumoto S, Yano K, Fujita N, Tsuruo T, Fujita T. Clonal endothelial cells produce humoral factors that inhibit osteoclast-like cell formation in vitro. Endocr J 2002; 49: 439-47.
24. Shahbazi S, Lenting PJ, Fribourg C, Terraube V, Denis CV, Christophe D. Characterization of the interaction between von willebrand factor and osteoprotegerin. J Thromb Haemost 2007; 5: 1956-62.
25. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Findlay DM, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is reduced at sites if inflammatory bone loss. J Cell Physiol 2005; 204: 714-23.
26. Baud'huin M, Duplomb L, Téletchéa S, Charrier C, Maillasson M, Fouassier M, Heymann D. Factor VIII-von Willebrand factor complex inhibitis osteoclastogenesis and controls cell survival. J biol Chem 2009; 284: 31704-13.
27. Kobayashi-Sakamoto M, Hirose K, Nishikata M, Isogai E, Chiba I. Osteoprotegerin protects endothelial cells against apoptotic cell death induced by Porphyromonas gingivalis cysteine proteinases. FEMS Microbiol Lett 2006; 264: 238-45.
28. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alphav beta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000; 275: 20959-62.
29. Chavakis E, Urbich C, Dimmeler S. Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol 2008; 45: 514-22.
30. Critser PJ, Yoder MC. Endothelial colony-forming cell role in neoangiogenesis and tissue repair. Curr Opin Organ Transplant 2010; 15: 68-72.
31. Zemani F, Benisvy D, Galy-Fauroux I, Bruel A, Vilar J, Lokajczyk A, Uzan G, Fischer AM, Boisson-Vidal C. Low-molecular weight fucoidan enhances the proangiogenic phenotype of endothelial progenitor cells. Biochem Pharmacol 2005; 70: 1167-75.
32. Smadja DM, Laurendeau I, Avignon C, Vidaud M, Aiach M, Gaussem P. Increased the angiopoietin pathway is modulated by PAR-1 activation on human endothelial progenitor cells. J Thromb Haemost 2006; 4: 2051-8.
33. Cheen PK, Paolo P, Malcolm RA. Endothelial progenitor cells and their potential therapeutic applications. Regen Med 2008; 3: 863-76.
34. Kobayashi-Sakamoto M, Isogai E, Hirose K, Chiba I. Role of αv integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Microvasc Res 2008; 76: 139-44.
35. Peters BA, Diaz LA, Polyak K, Meszler L, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, Kinzler KW, Lengauer C. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005; 11: 261-2.
36. Min JK, Kim YM, Kim YM, Kim EC, Gho YS, Kang IJ, Lee SY, Kong YY, Kwon YG. Vascular endothelial growth factor up-regulates expression of Receptor Activator of NF-B (RANK) in endothelial cells. J Biol Chem 2003; 278: 39548-57.
37. Kim HH, Shin HS, Kwak HJ, Ahn KY, Kim JH, Lee HJ, Lee MS, Lee ZH, Koh GY. RANKL regulates endothelial cell survival through the phosphatidylinositol 3'kinase/Akt signal transduction pathway. FASEB 2003; 17: 2163-5.
38. Pritzker LB, Scatena M, Gianchelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis inducing ligand in the human microvascular endothelial cell survival. Mol Biol Cell 2004; 15: 2834-41.
39. He T, Peterson TE, Holmuhamedov EL, Terzic A, Caplice NM, Oberley LW, Katusic ZS. Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol 2004; 24: 1977-9.
40. Kim YM, Kim YM, Lee YM. TNF-related Activation-induced Cytokine (TRANCE) Induces Angiogenesis through the Activation of Src and Phospholipase C (PLC) in human endothelial cells. J Biol Chem 2002; 277: 6799-805.
41. Lamoureux F, Picarda G, Garrigue-Antar L, Baud'huin M, Trichet V, Vidal A, Heymann D, Rédini F. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res 2009; 63: 526-36.
42. Marie P, Halbout P. OPG/RANKL role and therapeutic target in osteoporosis. Med Sci (Paris) 2008; 24: 105-10.
43. Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V, Blanchard F, Gouin F, Pitard B, Heymann D, Redini F. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007; 63: 7308-18.
44. Kobayashi-Sakamoto M, Isogai E, Holen I. Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src and ERK signaling in endothelial cells. Eur J Haematol 2010; 85: 26-35.
45. Mangan SH, Campenhout AV, Rush C, Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-associated with induction of Angiopoietin-2. Cardiovasc Res 2007; 76: 494-505.
46. Kindle L, Rothe L, Kriss M, Osdoby P, Collin-Osdoby P. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts. J Bone Miner Res 2006; 21: 193-206.
47. Zauli G, Secchiero P. The role of the TRAIL/TRAIL-receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 2006; 17: 245-57.
48. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 2009; 88: 1-17.
49. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009; 66: 841-51.